Physician profile
Robert C Patton
NPI 1831288901
$4,991.61
in general payments reported to CMS, 2019-2025
41 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $474 · 2021: $943 · 2022: $710 · 2023: $883 · 2024: $407 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $837.93 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Novo Nordisk INC | $482.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $292.53 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $268.27 | 2019-2024 | |
| Abbott Laboratories | $242.74 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $234.62 | 2019-2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $224.26 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Evoke Pharma, INC. | $218.33 | 2020-2023 | Gimoti |
| Janssen Pharmaceuticals, INC | $184.35 | 2020-2021 | |
| Amarin Pharma, INC. | $175.12 | 2019-2020 | |
| Abbvie INC. | $174.71 | 2020-2023 | |
| Amgen INC. | $161.67 | 2019-2023 | Repatha |
| Lilly USA, LLC | $144.07 | 2019-2024 | Mounjaro |
| Cook Medical LLC | $132.49 | 2021 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.